A Phase I Study of E7050 in Subjects With Solid Tumors

Phase 1 Completed 18 enrolled Eisai Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally once daily to patients with advanced solid tumor and gastric cancer.

Timeline

Start: 2011-09
Primary completion: 2013-01
Completion: 2013-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golvatinib	Small molecule	400 mg	Oral

A Phase I Study of E7050 in Subjects With Solid Tumors

Summary

Timeline

Drugs

Indications